Author:
El Sharawy Shimaa,El-Horany Hemat,Amer Ibrahim
Abstract
Background:
Serum biomarkers are commonly used for diagnosing and monitoring the disease activity of Ulcerative Colitis (UC) patients. However, their role in predicting disease severity among Egyptian patients is unknown.
Objectives:
The aim of this study was to correlate these biomarkers with clinical, endoscopic and histologic severity.
Methods:
This is a cross-sectional survey where 55 patients with UC were included to measure corrected Erythrocyte Sedimentation Rate (ESR), hematocrit (Hct), corrected ESR/albumin ratio and albumin, as well as colonoscopy and biopsy. Sensitivity and specificity, positive and negative predictive values were correlated with clinical, endoscopic, histologic severity.
Results:
The mean age of patients was 33 ± 8.4 years. In total, 27 (49.1%) were males and 28 (50.9%) were females. Area Under the Curve (AUC) values for the diagnosis of severe clinical disease were 0.947, 0.932, 0.727 and 0.685 for corrected ESR/albumin ratio, corrected ESR, Hct and albumin, respectively. Cut-off value to determine endoscopic severity for Hct was 34 (sensitivity: 88.89%, specificity: 83.78%, PPV: 72.7%, NPV: 93.9%, AUC: 0.963, p<0.001).
Conclusion:
Corrected ESR/albumin ratio was the best predictor of severe clinical activity of UC disease. Hct may be a marker of endoscopic and histological severity due to its high sensitivity and specificity as a diagnostic test.
Publisher
Bentham Science Publishers Ltd.
Subject
Biochemistry (medical),Clinical Biochemistry,Medicine (miscellaneous)
Reference46 articles.
1. Langholz E, Munkholm P, Davidsen M, Binder V.
Course of ulcerative colitis: Analysis of changes in disease activity over years.
Gastroenterology
1994;
107
(1)
: 3-11.
2. IIa T, IuI T.
Klin Med (Mosk)
2013;
91
: 27-33.
[Ulcerative colitis and Crohn’s disease. Part 1. Definition, terminology, prevalence, etiology and patogenesis, clinical features, complications, classification].
3. Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR.
Adacolumn leucocytapheresis for ulcerative colitis: Clinical and endoscopic features of responders and unresponders.
Expert Rev Gastroenterol Hepatol
2015;
9
(3)
: 327-33.
4. Abraham C, Cho JH.
Inflammatory bowel disease.
N Engl J Med
2009;
361
(21)
: 2066-78.
5. Baumgart DC, Sandborn WJ.
Inflammatory bowel disease: Clinical aspects and established and evolving therapies.
Lancet
2007;
369
(9573)
: 1641-57.